InsidersTradesSigma
Total declarations
Companies
▲ Purchases (27 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
27
Disclosed sells
1
T+90 hit rate
53%
T+90 mean return
+16.5%
Across 19 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by AKKARAJU SRINIVAS, Director. Officer active across 8 companies, notably Intercept Pharmaceuticals, INC.. Cumulatively, 54 filings have been logged. Breakdown: 27 buys · 1 sell. Total volume traded: €136.6m. Activity tracked since 27 May 2021. The latest transaction was disclosed on 4 June 2026 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations54 total
3,553 sharesCommon StockSEC:0001253170-26-000011:0
6,839 shares0Common StockSEC:0001104659-26-071422:0
244,300 shares@ US$4.8319.2% of flowCommon StockSEC:0001231919-26-000532:0
Ideal exit: 14 Feb 2027 (T+270)
66,906 shares0Common StockSEC:0001231919-26-000532:1
14,937 shares0Common StockSEC:0001231919-26-000532:2
4,471 shares0Common StockSEC:0001231919-26-000532:3
479,847 shares@ US$10.4280.8% of flowCommon StockSEC:0001231919-26-000166:0
Ideal exit: 14 Sept 2026 (T+270)
588,235 shares@ US$17.0024.7% of flowCommon StockSEC:0001253170-26-000004:0
Ideal exit: 6 Oct 2026 (T+270)
12,796 shares@ US$39.310.9% of flowCommon StockSEC:0001253170-25-000025:0
Ideal exit: 4 Jul 2026 (T+270)
12,400 shares@ US$40.180.8% of flowCommon StockSEC:0001253170-25-000025:1
Ideal exit: 4 Jul 2026 (T+270)
4,403 shares@ US$40.970.3% of flowCommon StockSEC:0001253170-25-000025:2
Ideal exit: 4 Jul 2026 (T+270)
1,064,804 shares@ US$7.3513.1% of flowCommon StockSEC:0001253170-25-000025:3
64,969 shares@ US$8.951.4% of flowCommon StockSEC:0001253170-25-000021:0
Ideal exit: 1 Sept 2026 (T+270)
70,028 shares@ US$10.011.7% of flowCommon StockSEC:0001253170-25-000021:1
Ideal exit: 1 Sept 2026 (T+270)
51,380 shares@ US$10.731.4% of flowCommon StockSEC:0001253170-25-000021:2
Ideal exit: 1 Sept 2026 (T+270)
11,011 shares@ US$35.610.7% of flowCommon StockSEC:0001253170-25-000006:0
Ideal exit: 30 Jun 2026 (T+270)
56,703 shares@ US$36.743.5% of flowCommon StockSEC:0001253170-25-000006:1
Ideal exit: 30 Jun 2026 (T+270)
319,700 shares@ US$37.4220.1% of flowCommon StockSEC:0001253170-25-000006:2
Ideal exit: 30 Jun 2026 (T+270)
18,414 shares@ US$37.891.2% of flowCommon StockSEC:0001253170-25-000006:3
Ideal exit: 3 Jul 2026 (T+270)
80,863 shares@ US$38.685.3% of flowCommon StockSEC:0001253170-25-000006:4
Ideal exit: 3 Jul 2026 (T+270)
13,748 shares@ US$39.520.9% of flowCommon StockSEC:0001253170-25-000006:5
Ideal exit: 3 Jul 2026 (T+270)
7,632 shares0Common StockSEC:0001104659-25-052478:0
1,214,582 sharesCommon StockSEC:0001415889-25-014559:0
138,368 shares@ US$4.581.6% of flowCommon StockSEC:0001415889-25-012166:1
Ideal exit: 30 Jan 2026 (T+270)
22,002 shares@ US$5.270.3% of flowCommon StockSEC:0001415889-25-012166:2
Ideal exit: 30 Jan 2026 (T+270)
25 of 54 declarations
About AKKARAJU SRINIVAS
Akkaraju Srinivas is a Board Member at Intercept Pharmaceuticals, Inc. and Chinook Therapeutics, Inc. He brings his expertise in corporate governance and strategy to these companies. His role involves overseeing operations and ensuring that decisions made by the board are in the best interest of shareholders and stakeholders. With his experience, he contributes to strategic direction and risk management within these biopharmaceutical companies.
